New pill aims to slow Parkinson's progression in Early-Stage patients
NCT ID NCT07280299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called GT-02287 in 111 people with early Parkinson's disease. Participants will receive either a low dose, high dose, or placebo for 48 weeks. The goal is to see if the drug improves daily movement and motor symptoms, and to check its safety and effects on disease-related biomarkers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood-flow cuffs may mimic exercise to ease Parkinson's symptoms
- Shake or sync: two therapies put to the test for Parkinson's mobility
- Wearable sensors aim to catch neurodegenerative decline in real time
- Can deep brain stimulation rewire faulty movement circuits? a surgery-time study aims to find out.
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Could a simple bowel rinse ease Parkinson's constipation and movement problems?